06:01 AM EDT, 05/08/2026 (MT Newswires) -- Novo Nordisk (NVO) saw a 40% month-on-month surge in April sales of its diabetes and weight-loss drugs in India after slashing prices, despite a flood of generic versions, Bloomberg News reported Friday, citing data from market researcher Pharmarack.

April marked the first full month since generic semaglutide entered the Indian market.

Sales of Wegovy, Ozempic and partner-branded versions increased to 32,000 units last month, while cheaper generics helped expand the overall market 56% to 414,000 units, according to the report.

The aggressive pricing helped the Danish drugmaker defend its market share against low-cost rivals, a Pharmarack executive told Bloomberg News.

Novo Nordisk did not immediately respond to MT Newswires'request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)